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Background: Cancers produce soluble and cell-associated molecules that can suppress or alter antitumor immunity.
Preclinical studies suggest the disease burden may alter the cytokine profile of helper T cell responses to cancer
antigens. We studied cytokine production by helper T cells responding to vaccination with 6 melanoma helper
peptides (6MHP) in blood and lymph nodes.
Methods: Twenty-three patients with stage IIIB-IV melanoma received a 6MHP vaccine. Antigen-reactive T cells from
blood and draining lymph nodes were cultured, exposed to antigen, and then supernatants (days 2 and 5) were
assayed for Th1 and Th2 cytokines. Results from 4 time points were compared to pre-vaccine levels.
Results: Cytokine responses to vaccinating peptides were observed in 83% of patients. Th1 favoring responses
were most common (17 of 19 responders). The most abundant cytokines produced were IFN-γ and IL-5 in the
PBMC’s. IL-2 responses predominated in cells obtained from draining lymph nodes in 2-day culture but not in 5-day
cultures. Patients with clinically measurable disease produced similar levels of total cytokine and similar degree of
Th1 polarization as patients with no evidence of disease (NED).
Conclusions: The MHC class II-associated peptides used in this study induced helper T cells with a Th1-biased
cytokine response in both PBMC and sentinel immunized nodes. Most patients can mount a Th1 dominant response to
these peptides. Future studies are needed to test newer vaccine adjuvants in combination with these peptides.
Trial registration: CDR0000378171, Clinicaltrials: NCT00089219.
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vaccinesBackground
Most antigens selected for peptide-based cancer vaccines
have been MHC class I restricted; they elicit predomin-
antly CD8+ cytotoxic T-cell responses. The roles for
MHC class II associated helper peptides and the CD4+
T-cells which they stimulate have often been viewed as
secondary mechanisms in immunotherapy. Nevertheless,
it is known that CD4+ T lymphocytes are important in
generating effector T cell responses, in “licensing” den-
dritic cells, and in maintaining immunologic memory* Correspondence: cls8h@virginia.edu
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unless otherwise stated.[1-4]. They mediate their effects, in part, by the cyto-
kines they produce. The Th1 favoring cytokines (e.g.:
IFN-γ, TNF-α, and IL-2) classically support cytotoxic T
lymphocyte (CTL) responses, while the Th2 cytokines
(e.g.: IL-4, IL-5, IL-10) support generation of antibody
responses and may be antagonistic to induction of CTL
responses.
We previously employed a tetanus helper peptide
AQYIKANSKFIGITEL to stimulate helper T cells. The
tetanus helper peptide has been immunogenic and in-
duced Th1-predominant responses [5]. More recently,
we have evaluated a multi-epitope vaccine incorporating
6 melanoma helper peptides (6MHP), restricted by
HLA-DR molecules, that function as epitopes for CD4+td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Dillon et al. Journal for ImmunoTherapy of Cancer 2014, 2:23 Page 2 of 11
http://www.immunotherapyofcancer.org/content/2/1/23T cells. This 6MHP vaccine used in the current study is
proven to be safe and shows some evidence of clinical
activity as previously published [6]. Clinically, objective
response was observed in 2 of 17 patients (12%) with
measurable disease [6]. The vaccine induced antigen-
specific CD4+ T cell responses in over 80% of patients.
We previously showed that all 6 helper peptides used for
this study are immunogenic and that MAGE-A3281-295
and tyrosinase386-406 have the most frequent responses
[6,7]. Since, the cytokine profile of responding T cells is
not previously reported we now report on cytokine pro-
files of helper peptide vaccinated patients.
Prior in vitro work with human peripheral blood
mononuclear cells (PBMC) suggested that disease sta-
tus (advanced measurable disease vs. clinically free of
disease) may direct the Th1/Th2 dominance of T cell
responses to helper peptides. In patients bearing meas-
urable advanced renal cell cancer, T cell responses were
generated in vitro with dendritic cells (DC) pulsed with
helper peptides from MAGE-A6, and responses were
highly Th2 dominant, manifested primarily by high
IL-5 secretion [8]. In contrast, lymphocytes from pa-
tients rendered clinically free of disease by surgery had
Th1-dominant responses to the same helper peptides,
manifested by high secretion of IFN-γ [8]. The current
report is intended to assess whether T cell responses to
vaccination with 6 melanoma helper peptides (6MHP)
are predominantly Th1 or Th2 dominant, and to ob-
tain preliminary data on whether Th1/Th2 dominance
varies as a function of clinical disease status.
Results
Cytokine profiles from 23 vaccinated stage III and IV
melanoma patients were assessed from PBMC’s and
draining lymph nodes. The lymph nodes collected at day
22 of the 6-vaccine series were surgically resected from
the draining nodal basins most proximal to the vaccine
sites (sentinel immunized nodes, SIN). We assessed the
Th1 favoring cytokines: IFN-γ, TNF-α and IL-2, and the
Th2 favoring cytokines: IL-4, IL-5 and IL-10. There were
three dose arms in the study, and there were no differences
in toxicity nor response by dose (previously published) [6].
The cytokine profiling is performed on supernatants from
cultures of lymphocytes derived from draining nodes and
from peripheral blood.
The Th1/Th2 cytokine profiles of T cell responses to
helper peptide vaccination
Cytokines secreted by peripheral blood mononuclear
cells (PBMC) and sentinel immunized node (SIN) lym-
phocytes were measured 2 days after pulsing them with
the vaccinating 6 helper peptide pool. Th1 and Th2
cytokine production in response to the 6MHP pool is
shown in Figure 1 for PBMC’s pre and post-vaccine.Cytokine levels post-vaccine were not different among
dose arms of the study (all p values >0.05). An increase
in total cytokine production by PBMC’s was observed
in 19 of 23 patients (83%) from baseline (pre-vaccine)
to post-vaccine, and responses greater than 4 times
baseline were seen in 14 of 23 (61%). In terms of cyto-
kine polarization for PBMCs post-vaccine, 17 of 19
responding patients had Th1 predominant responses;
one patient had a Th2 predominant response.
The most abundant individual cytokine detected in re-
sponse to helper peptide vaccination was IFN-γ, increas-
ing from baseline of 8.7 to 121 pg/ml (Table 1) in
PBMC’s. In terms of Th2 favoring cytokines, IL-5 was
often induced by vaccination, but in relatively lower
abundance than IFN-γ (post-vaccine mean of 20.7 pg/ml).
Overall, IL-5 production increased in 14 of 23 patients.
Changes in IL-4 and IL-10 were rarely significant and rarely
changed above background controls. The values for SIN
and additional PBMC values are listed in the tables. Values
on the tables and figures reflect background adjustment
and raw cytokines values were generally within the linear
range of the cytokine bead assay (94%).
Cytokine profiles over time are shown for representa-
tive patients in Figure 2 (and Additional file 1). The
figures demonstrate examples of enhanced cytokine pro-
duction following helper peptide vaccination. It is evi-
dent that cytokine production fluctuates over time for
certain cytokines. The primary discernible trend ob-
served over 7 weeks is that patients tend to maintain
their individual cytokine predominance, i.e. a Th1 pre-
dominant initial response tends to persist. Likewise, in
the single patient with a Th2 predominant PBMC pro-
file, that profile persisted throughout the observation
period (patient 11, Figure 2).
5 Day lymphocyte culture increases overall cytokine
production, but decreases IL-2 production
Cytokine production for 11 patients was analyzed by 5
day culture methodology (otherwise identical to 2-day
culture). The overall magnitude of cytokine response
was greater after 5 day culture for all patients (p = 0.003,
Table 2), although variability is seen when examining in-
dividual cytokines. Individual cytokine levels were sig-
nificantly greater on day 5 than day 2 for IFNγ, IL-2, and
IL-5. The Th1 and Th2 cytokine levels are shown for
each of those 11 patients in Additional file 1: Figure S1.
Eight of the eleven patients had Th1 dominant responses
post-vaccine, two had Th2 dominant responses (11, 18),
and one had a balanced profile (22). The profiles in SIN-
derived lymphocytes were similar, with 6 of 9 having
Th1-dominant responses, one having a Th2 response
and two having no response. In these 5 day supernatants
from SIN derived lymphocytes, IFN-γ replaced IL-2 as the
highest measured cytokine. The differences in cytokines
Table 1 Summary of 2-day response data
PBMC (n = 23) SIN (n = 22)
Cytokine Mean pre-vaccine (pg/ml) Mean post-vaccine (pg/ml) Number with increase (p value) Mean at day 22
IFN-γ 8.7 121 15 (p = 0.04) 51.2
IL-2 0.8 13.7 15 (p = 0.07) 62.3
TNF-α 15.2 16.1 10 (p = ns) 4.4
IL-4 0.8* 5.0* 7 (p = ns) 2.8
IL-5 0.2 20.7 14 (p = ns) 12.7
IL-10 1.1* 1.6* 9 (p = ns) 2.1
Th1 sum 24.8 150.9 17 (p = 0.036) 118
Th2 sum 2.1 27.3 14 (p = 0.042) 17.6
IFN vs IL-5 0.2 vs 8.7 20.7 vs 121 p = 0.005 p = 0.010
Th1 NED 12.1 174
p = 0.091
162
Th1 Disease 41.2 111 66
Total cytokines NED 14.3 211
p = 0.11
188
Total cytokines Disease 43.1 120 65
Means of cytokines and assessments of individual cytokine responses to vaccination with 6MHP. Increase from baseline required values within linear range of
cytokine assay. Mean values reflect aggregate activity and outliers are notable as seen in the figures. All values are corrected for background PBMC is peripheral
blood mononuclear cells and SIN are sentinel immunized nodes. NED = no evidence of disease.
*Some samples zeroed based on background correction.
Figure 1 Individual patient cytokine production pre and post vaccine. The cytokine profiles for patients treated with 6 melanoma
helper peptide vaccine. Cytokines were measured from PBMC’s cultured for 2 days with the 6 melanoma helper peptide mixture. Cytokines
are shown in pg/ml. Arm A (patients 1-9) received 200 mcg, Arm B (patients 10-15) received 400 mcg and Arm C (patients 16-23) received
800 mcg. Cytokine cultures were performed in triplicate. All cytokine levels shown are corrected for background and negative control. Axes
were scaled to show relative change from baseline. The ranges for the vertical differ between plots based on absolute cytokine level. IL-4
and IL-10 are available as Additional file 1: Figure S6.
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Figure 2 Cytokine production at different time points following helper peptide vaccination. Cytokine levels in 5-day supernatants are
shown for 6 patients with proliferative responses to 6MHP vaccination whose PBMC were evaluated after stimulation with 6MHP. Th1 and Th2
cytokines are represented by stacked bars. The time in weeks after first vaccine is shown on the x-axis. The SIN was collected at day 22. The prior
node for patient number 21 was collected prior to helper peptide vaccination and was analyzed with permission. It is included to illustrate the
pre-vaccine cytokine milieu of the lymph nodes.
Table 2 Comparison of 2 day to 5 day cytokine responses
2 Day (n = 23) 5 Day (n = 11) t-test*
IFN-γ 112 1380 0.03
TNF-α 17 92 0.45
IL-2 12 0.1 0.004
IL-10 1.6 12 0.062
IL-4 4.4 3.2 0.8
IL-5 20 267 0.02
Total 178 1756 0.003
Summary of cytokine values at 2-day culture versus 5-day culture following
6MHP vaccination. Mean cytokine at peak time point are shown in pg/ml and
mean values are shown. Value are background and baseline corrected. Bold
face highlights p-values <0.05. *The 5 day analysis represents a subset of the
2 day cohort so this is a descriptive analysis only.
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ploratory endpoint, with significance levels shown in
Table 2. Also notably, neither of the Th2 responders had re-
ceived prior chemo.Clinical outcomes
The RECIST clinical response rate was 12% for the study
[6]. Among the 23 patients evaluated for cytokine pro-
files, 11 had advanced metastatic disease, and 12 had no
evidence of disease (NED) due to resected stage III or
resected stage IV status. The IFN-γ change pre-vaccine
to post-vaccine in the 2 day assay was 137 pg/ml in the
NED group and 67 pg/ml in the metastatic group (p =
0.33, t-test). The IL-5 response was similar between
groups (28.1 g/ml for NED and 5.5 pg/ml for metastatic,
p = 0.93, t-test). No statistically significant difference in
Figure 3 Individual Cytokine Profiles; Medians by disease state. Cytokine responses are compared by disease state where NED indicates
no evidence of disease. Disease indicates unresectable metastatic melanoma. Median cytokine production is shown as stacked bars. SIN were
collected at day 22. This is a 2-day culture assay where n = 23. All values are background corrected. Post-vaccine indicates the time point with
highest magnitude of response and may differ for individual patients. This figure is shown to display relative proportions of individual cytokines,
specifically the relative contribution of IL-2. There is no statistical difference between disease status groups overall.
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Figure 3. Individually, one of 11 metastatic patients had
a Th2-dominant response and no patients in the NED
group had a Th2 response. Examination of the SIN cyto-
kine production also failed to show a statistically signifi-
cant difference in cytokine production by disease status
(Table 1). Individually, one of 12 SIN in the NED group
and none in the metastatic group had Th2-dominant
responses.
In terms of survival, we observed that stage III and IV
patients who were NED at the time of the vaccination
achieved a mean survival of 4.9 years. The mean survival
for patients with clinically measurable disease was 2.5
years. The 4 patients who had partial responses or stable
disease by RECIST had nothing unique about their cyto-
kine profiles at any of the 4 time points tested. They
were all Th1 favoring responders by cytokine profiling.
We previously reported that those 4 clinical responders
all had proliferative responses to vaccine, delayed-typed
hypersensitivity and autoimmune phenomena. Due to
the small number of responders, we did not find sig-
nificant correlations between any of the cytokines and
clinical response.
Th1/Th2 bias on a per-cell basis
Relative concentrations of Th1 and Th2 cytokines from
bulk lymphocyte cultures may not accurately represent
the Th1 or Th2 bias of responding lymphocytes. A
measure with biologic relevance is the number of CD4+
cells secreting Th1 cytokines compared to the numbersecreting Th2 cytokines. Since IFN-γ and IL-5 were the
predominant Th1 and Th2 cytokines in our assays, we
measured those cytokines in helper T cells (CD8neg) pro-
liferating 5 days in response to the 6MHP mixture for
two representative patients by flow cytometry. CD4 can
be downregulated after stimulation [9]; so positive selec-
tion of CD4+ T cells for this analysis could have been
limited by downregulation of CD4 expression after
antigen exposure. Thus, as a surrogate for proliferating
CD4+ cells, we used proliferating CD3+CD8neg cells defined
by CFSE dilution. Among proliferating CD3+CD8neg cells,
IFNγ-secreting cells were 3- to 10-fold more prevalent than
IL-5 secreting cells as measured by flow cytometric analysis
(Figure 4). These findings correlated well with cytokine
measurements in supernatants for the corresponding pa-
tients (patients 8 and 9). Among proliferating CD3+CD8neg
cells for patient 8, IL-5 was produced by only 4% of PBMC
(collected week 5) and 4% of SIN lymphocytes, whereas
IFN-γ was produced by 36% of PBMC and 35% of SIN lym-
phocytes (Figure 4). For a second patient (#9), IL-5 and
IFNγ-secreting cells were 9% and 28% of CFSE-diluted
cells, respectively, in PBMC (week 3) and 8% and 24% in
the SIN (data not shown).
Cytokine profiles in sentinel immunized nodes are not
impacted by prior vaccination with class I associated
peptides
A Th1 cytokine predominance was observed in 21 of 22
sentinel immunized nodes harvested at 3 weeks from the
first vaccine (2-day assay, Figure 5). The most abundant
CFSE



















Figure 4 Cytokine secretion in response to 6MHP stimulation. PBMC (week 5, left panels) and SIN lymphocytes (day 22, right panels) were
stimulated with 6MHP after CFSE labeling, then tested for IL-5 (top panels) production or IFN-γ (bottom panels) production. Data are shown for
cells from a representative patient (patient 8) gated on lymphocytes, CD3-positive, and CD8-negative. The cells secreting cytokine are represented
in the left upper quadrant of each plot, with percentages shown for each quadrant. IFN-γ producing cells are 8-9 fold more prevalent than IL-5





























Arm A        Arm B                 Arm C             
Th-1
Th-2
Figure 5 Cytokine response in sentinel immunized lymph nodes. Cytokines were measured from lymphocytes collected from sentinel immunized
lymph nodes cultured for 2 days with the 6 melanoma helper peptide mixture. Arm A (patients 1-9) received 200 mcg, Arm B (patients 10-15) received
400 mcg and Arm C (patients 16-23) received 800 mcg. Cytokine cultures were performed in triplicate. All cytokine levels shown are corrected
for background and negative control. The node was not able to be collected from patient #14.
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IL-2, rather than IFN-γ, which was predominant from
PBMC. Individually 17 lymph node samples had IL-2 as the
predominant cytokine, while 3 produced more IFN-γ than
IL-2 (and 2 were low producers). Due to the invasive nature
of a lymph node biopsy, baseline nodes were not obtained
for comparison as part of this trial, but 3 patients had had
lymph nodes removed in other vaccine trials prior to this
study. The three patients who had been on prior vaccine
trials (Mel 36, 37, 39) [10-12] did not receive prior
melanoma helper peptides. For these patients, we eval-
uated the response of SIN lymphocytes to the 6MHP,
compared to SIN data from the present trial. In re-
sponse to stimulation with the 6MHP, there was no de-
tectable cytokine response in the pre-Mel41 lymph
node cells (Figure 6). After 3 weeks of vaccination with
6MHP, proliferative responses to the 6MHP were
observed [6], and strong cytokine responses were de-
tected for two of the three patients (Figure 6).Discussion
Helper peptides for cancer vaccination have previously
been shown to be immunologically important both alone
and as adjuvants [5,13]. We previously observed that other
helper or class II peptides evoked Th1 dominant cytokine
responses from stimulated lymphocytes [12] and now
hypothesize that helper peptides specifically from melan-
oma antigens would also produce Th1 favoring responses.
Further, based on published work [8], we hypothesized that
































Figure 6 Cytokine production from SIN lymphocytes in response to 6
responses for 3 patients from prior type I vaccine studies. SIN lymphocytes from
were harvested at 40-48 h, and then evaluated with cytokine bead array (CBA) f
patients were evaluated with cytokine bead array after 3 doses of 6MHP vaccina
preclude a response to type II peptide vaccination.The cytokine profiles of T cells induced by the helper
peptides in this vaccine are most consistent with a Th1
dominant profile in 14 of 19 responders (74%) of re-
sponders. Interestingly, 2 patients had a Th2-dominant re-
sponse (one for the 2-day assay and one for the 5-day).
Balanced Th1/Th2 responses occurred in 3 patients. Th-1
responses are believed to be most supportive of phagocytic
and cytotoxic type tumor responses; the induction of Th2
dominant responses in two patients may be antagonistic to
the induction of protective immunity.
It is not known whether the observed Th2 responses
represent induction of new Th2 responses, a selective
depletion of Th1-responding cells, or a suboptimal vac-
cination strategy. Future studies to identify molecular
mediators of Th2 responses and to characterize further
the pleiotropic effects of these cytokines may be inform-
ative. Likewise, future evaluation of Th-17 responses
elicited by helper peptides is also needed and may fur-
ther elucidate the relative contribution of Th-2 cytokines
in helper responses. In this study, most patients main-
tained a Th1 dominant response throughout the course
of vaccine therapy (Figure 5). Analysis of delayed type
hypersensitivity data [6] also supports an immune re-
sponse up to 9 months. Questions remain about the
need for booster vaccines; these data do not rule out the
possibility that booster vaccines may favorably modify
the helper T cell response.
The total cytokine production significantly increased
from 2 day to 5 day culture, which is not surprising;
however, high IL-2 levels were seen in draining nodes in
2 day cultures which were not seen in 5 day node cul-









MHP stimulation in 3 patients with prior vaccinations. The SIN
pre-vaccine lymph nodes were cultured with the 6MHP, and supernatants
or levels of Th1 and Th2 cytokines. The SIN lymphocytes from the same
tion. Notably, prior vaccination with type I peptides does not seem to
Dillon et al. Journal for ImmunoTherapy of Cancer 2014, 2:23 Page 8 of 11
http://www.immunotherapyofcancer.org/content/2/1/23cells, during longer culture and could apply either to ex-
pansion of activated T cells or induction of regulatory T
cells, both of which express the high affinity IL-2 recep-
tor alpha chain (CD25) [14]. Central memory T cells
(TCM) respond to antigen by high IL-2 production [15],
thus, the disparate cytokine profiles in the SIN and
PBMC suggest that antigen reactive cells in the node
(but not in the PBMC) may be enriched for TCM. The
loss of IL-2 dominance as TCM respond to antigen and
proliferate is also consistent with that observation.
While nearly all patients maintained their overall
cytokine profile over time, in a few cases, the Th2/Th1
ratio increased in culture over time, toward slightly
lower Th1 predominance. These anecdotal cases highlight
the relevance of following immunologic endpoints over
time and also highlight the wide degree of variability seen
when dealing with human immune monitoring.
It has been reported that PBMC from patients with ad-
vanced measurable malignancy may have Th2-dominant re-
sponses to helper peptides, whereas those rendered
clinically free of disease may have Th1-dominant responses
[8]. Our study differs from that report in part by being in
melanoma patients rather than renal cell cancer, but more
importantly because the induction of the T cell response
was in vivo (tested in vitro) rather than being induced
in vitro. Our findings do show non-significant trends to-
ward that prior observation, since the only Th2-dominant
responses we observed in either 2 or 5 day assay were in
metastatic patients with measurable disease, and all of the
12 NED patients had a Th1-dominant response. Also, the
total cytokine produced in NED patients trended higher
than among those with measurable disease. However, these
were not significant differences and were much less pro-
nounced than the prior data after in vitro sensitization.
Overall, Th1-dominant responses were most common
among both subsets of patients. Anecdotally, prior chemo-
therapy exposure was not associated with either of two Th2
responses observed.
The observed cytokine response rate of 83% mirrors
the proliferative response rate previously reported (81%),
but neither immune assay correlates well with the clin-
ical response rate of 12%. The median overall survival
for stage IV patients in this study was 2.5 years which is
very favorable, but may be influenced by referral bias. In
another study with this 6MHP vaccine, immune re-
sponses to these 6MHP were strongly and significantly
associated with overall survival [13]. However, helper
peptide vaccination remains experimental. Further work
is needed to optimize adjuvants and to identify measures
of immune response associated with favorable outcome.
Since this study was designed, we have found that GM-CSF
decreases both CD4+ and CD8+ responses to melanoma
vaccines in incomplete Freund’s Adjuvant [16]; thus, we an-
ticipate that vaccination with melanoma helper peptideswithout GM-CSF or in different adjuvant systems may be
even more effective at inducing high magnitude Th1-
dominant immune responses.
Conclusions
The MHC class II-associated peptides used in this study
induced helper T cells with a Th1-biased cytokine re-
sponse in both PBMC and sentinel immunized nodes.
IL-2 was the dominant Th1 cytokine produced early
from SIN, but not from PBMC, and this is consistent
with a central memory response in the SIN, which is not
surprising since TCM are expected to reside in lymphoid
organs. There were exceptions in that several patients
had cytokine responses that were either Th2-dominant
or Th1-Th2 balanced. The analysis of cytokine profiles
over time also suggests that induced helper T cells re-
spond in a specific and stable manner when re-exposed to
vaccinating peptides. Clinical disease status did not bias the
cytokine polarization in a significant way, though the over-
all magnitude of cytokine production trends higher in pa-
tients without clinically evident disease. Studies in larger
patient populations may find significant differences that
were not evident here, and if so, that could support differ-
ent immunotherapy approaches depending on the clinical
disease status. Thus, as vaccine adjuvants are improved,
analysis of the effects on cytokine profiles in blood and
nodes may help to identify patients who may benefit most
from helper peptide vaccines.
Methods
Patients
Patients with AJCC stage IIIB, IIIC or IV melanoma with
or without measurable disease were eligible for this vac-
cine trial. Candidates were required to express at least
one of the 5 HLA-DR alleles by which CD4 T cell recog-
nition for these 6 peptides had been defined: HLA-DR1,
DR4, DR11, DR13, DR15. Other inclusion criteria and
details of the study have been reported [6]. Patients were
studied following informed consent, and with Institu-
tional Review Board (HIC#10464) and FDA approval
(BB-IND #10825). Baseline demographics are described
in Additional file 1: Table S3.
Vaccine composition
All patients received a vaccine comprising 6 melanoma
peptides reported to be restricted by one or more HLA-DR
molecules. The peptides and their reported HLA-DR
restrictions are AQNILLSNAPLGPQFP (Tyrosinase56-70,
HLA-DR4) [16], FLLHHAFVDSIFEQWLQRHRP (Tyro-
sinase386-406, HLA-DR15) [17], RNGYRALMDKSLHV
GTQCALTRR (Melan-A/MART-151-73, HLA-DR4) [18],
TSYVKVLHHMVKISG (MAGE-3281-295, HLA-DR11)
[19], LLKYRAREPVTKAE (MAGE-1,2,3,6121-134, HLA-
DR13) [20], and WNRQLYPEWTEAQRLD (gp10044-59,
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added at the N-terminus of AQNILLSNAPLGPQFP
(Tyrosinase56-70), to prevent cyclization of the N ter-
minal glutamine residue in the originally described
sequence QNILLSNAPLGPQFP [16,23]. They were pre-
pared under good manufacturing practice (GMP) condi-
tions as described [6].
The peptides were administered with 110 mcg GM-
CSF (Berlex, Seattle, WA) in a stable emulsion with 1 ml
Montanide ISA-51 adjuvant (Seppic, Inc., Paris, France/
Fairfield, NJ) days 1, 8, 15, 29, 36, and 43 (weeks 0, 1, 2,
4, 5, and 6). The first 3 vaccinations were divided be-
tween two injection sites (primary and replicate), and
the last 3 vaccinations were delivered to the primary
injection site only. At each injection site, half was ad-
ministered subcutaneously and half was administered
intradermally. Vaccine was administered at 3 dose levels
(200 ug, 400 ug and 800 ug, arms A, B and C) with no
differences in AE’s nor responses between the dose levels
(previously reported). In addition to peptides used in the
vaccine, a tetanus helper peptide AQYIKANSKFIGITEL
and the irrelevant peptide from HIV gag protein, SLYNT
VATL were used in laboratory analyses [11,24].
Collection of peripheral blood mononuclear cells (PBMC)
Blood was drawn weeks 0, 1, 3, 5, 7, 12, and 18, and at
months 6, 9, 12, 18, and 24. Those drawn on weeks 1,
3, 5, and 7 correspond to one week after vaccines 1, 3, 4,
and 6, respectively. Lymphocytes isolated from periph-
eral blood by Ficoll gradient centrifugation were cryo-
preserved in 10% DMSO/90% serum. Several vaccinated
patients were unable to complete all blood draws or had
non-viable lymphocytes at time of cytokine analysis; 23
of 37 patients had a minimum of 3 time points with
adequate and viable lymphocytes.
Harvest of the sentinel immunized node (SIN)
On day 22 (week 3), the lymph node draining the repli-
cate immunization site, the sentinel immunized node
(SIN), was localized and harvested under local anesthesia
as reported [25,26]. A central slice of the SIN was pre-
served in formalin, and the remainder was dissociated
mechanically into a single cell suspension of lympho-
cytes, and cryopreserved by the University of Virginia’s
Tissue Procurement Facility.
Proliferation and cytokine assays
Responses to the six melanoma helper peptides were
assessed in vitro by measuring proliferation after an-
tigen exposure. PBMC were thawed in RPMI 1640
medium with 5% heat inactivated human AB serum
(HuAB; Gemini Bio-Products, West Sacramento, CA)
and DNAse (Worthington Biochemical Corporation,
Lakewood, New Jersey, Cat # LS002139; 100 mg, 2,430units/mg dry weight) at 100 U/ml and washed twice.
Cells were adjusted to 1×106 cells/ml in tissue culture
medium consisting of AIM V (Invitrogen Corporation/
GIBCO, Carlsbad, CA) with heat inactivated 10% HuAB
serum, plus each of the following 11 conditions: 1) media
only; 2) bovine serum albumin (BSA; Sigma-Aldrich, St.
Louis, MO; 10 ug/ml); 3) tetanus peptide (10mcg/ml); 4-9)
each of the 6 melanoma helper peptides (10 mcg/ml, indi-
vidually tested); 10) 6 melanoma helper pool (6MHP; all 6
peptides at 10 mcg/ml per peptide); and 11) PHA (Sigma;
at 5 mcg/ml). PBMC from two normal donors (Virginia
Blood Services, Charlottesville, VA) were included as con-
trols and were stimulated with each of the following 13
conditions: 1) media only; 2) BSA; 3) Tetanus peptide; 4-9)
6-melanoma peptide pool; 10) PHA; 11) influenza lysate,
12) lysate control (Microbix Biosystems Inc., Toronto,
Ontario); or 13) PHA. Cultures were assayed in tripli-
cate in 96-well flat bottom cluster dishes and were in-
cubated 5d at 37°C and 5% CO2.
Cytokine assays
On day 2 or day 5 of the 5-day proliferation assay cultures
described above, 50 μl supernatant was removed from each
well of the triplicate cultures, pooled and stored at -80°C
until tested for Th1 (IFN-gamma, IL-2, TNF-alpha) and
Th2 (IL-4, IL-5, IL-10) cytokines by cytokine bead array
(BD Biosciences, Franklin Lakes, NJ).
CFSE labeling and in vitro stimulation
Cryopreserved PBMC were thawed in pre-warmed medium
(RPMI 1640 + 5% fetal calf serum) containing DNase
(Worthington Biochemical Corp., Lakewood, NJ) at 100
units/ml. Viability was determined by Trypan blue dye ex-
clusion, and viable cells were adjusted to 2-4 million/ml in
0.2% BSA in PBS. Cells were labeled using the Vybrant
CFDA SE Cell Tracer kit (Invitrogen Corporation/Molecu-
lar Probes). Carboxy-fluorescein diacetate, succinimidyl
ester (CFDA SE; referred to hereafter as CFSE) was dis-
solved in DMSO to 10 mM. and diluted to 1 μM in PBS.
Equal volumes of cells and dye were combined, incubated
10 minutes at 37°C then washed in AIM V (Gibco/Invitro-
gen) supplemented with heat inactivated 5% HuAB serum.
After stimulation 5d at 37°C with peptide (10 ug/ml) or
CD3/CD28 beads (Miltenyi Biotec, Inc., Auburn, CA), cells
were collected and prepared for flow cytometric analysis.
Immunological reagents for flow cytometry
Fluorescent tagged antibodies used were specific for: CD3
allophycocyanin (APC), CD3 APC-cyanine7 (Cy7), CD4
phycoerythrin (PE), IL5 PE (BD Biosciences, San Jose CA);
CD8 PE-Cy7 (Beckman Coulter Miami FL); IFN-gamma
APC, FoxP3 (clone PCH101) and its isotype control
(eBiosciences, San Diego CA); CD25-PE (Miltenyi Biotec
Inc, Auburn CA).
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Intracellular cytokine (ICC) production by proliferating
cells was determined on peptide-stimulated CFSE-labeled
PBMC after phorbol 12-myristate 13-acetate (PMA;
40 ng/ml; Sigma-Aldrich) plus ionomycin (1 μM; Sigma).
Brefeldin A (10 μg/ml; Sigma-Aldrich) was added to cul-
tures after one hour. After stimulation of PBMC with the
pool of 6MHP for 5 days, PMA and Ionomycin in the
presence of Brefeldin A was added for 5 additional hours
detect cytokines produced by dividing cells. For flow
cytometric analysis, the CD3posCD8neg T cell population
served as a surrogate CD4 population because PMA
is known to down-modulate surface CD4. Cells were
harvested 5h later and surface-stained with anti–CD3
APC-Cy7 and –CD8-PE-Cy7, then washed, fixed and
permeabilized (Cytofix/CytoPerm™, BD Biosciences) be-
fore staining with anti-IL5 PE and anti-IFN-gamma APC.
Cells were collected on a modified Becton Dickinson
FACSCalibur dual laser (488 nm and 637 nm) benchtop
cytometer (FACSCalibur A) capable of 7 parameter (five
color) analysis. Data were analyzed with FloJo (Treestar,
Ashland OR) software. Gates and parameter thresholds
were set using unstained cells as controls.Statistical methods
Positive and negative controls were performed and all
results adjusted accordingly. Non-specific and back-
ground cytokine production was accounted for by use of
controls and baseline subtraction. Cytokine levels were
rescaled using the square root transformation for some
figures, and in the case of PBMC’s, readjusted by sub-
traction of the baseline cytokine level. Summary statis-
tics were calculated for levels of cytokine. Paired and
two sample t-tests were used to compare cytokine levels
across various factors. Levels of cytokine were assessed
across treatment arms using linear regression methods.
Survival function was performed in SAS. The overall
study was not powered for assessing multiple cytokine
profiles, however cytokine profiling by study arm and
disease status were pre-planned analyses in the study
protocol.Additional file
Additional file 1: Table S1. Peptides and parent proteins in this study.
Table S2. Updated patient survival table (as of 3/14/2014). Table S3.
HLA-DR distribution. Figure S1. This figure shows the cytokine response
to 6MHP vaccination upon 5-day culture. Figure S2. This figure demonstrates
the breadth of cytokine response to for a single patient to each of the relevant
helper peptides. Figure S3. This figure is a tally of the sum of the
means of Th1 and Th2 favoring cytokines measured in PBMC at their
highest post-vaccine time point. Figure S4. Day 2 and 5 Interferon-γ
Responses to 6MHP, means by arm. Figure S5. Flow cytometry experiment
demonstrating change in CD4+, CD25hi, FoxP3+ regulatory T cells following
helper peptide vaccination. Figure S6. These figures are the additionalcytokines not shown in figure #1. Figure S7. This figure provides additional
plots to figure 2. Table S4. sample data table illustrating patient variability.
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